Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bladder Carcinoma in Situ (CIS)”

55 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 55 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07189793
What this trial is testing

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

Who this might be right for
Urinary Bladder NeoplasmsCarcinoma, Transitional CellCarcinoma in Situ of Bladder+1 more
First Affiliated Hospital of Wenzhou Medical University 106
Large-scale testing (Phase 3)Study completedNCT01316874
What this trial is testing

Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)

Who this might be right for
Carcinoma in SituBladder Cancer
Endo Pharmaceuticals 90
Large-scale testing (Phase 3)Study completedNCT00003779
What this trial is testing

Biological Therapy in Treating Patients With Bladder Cancer

Who this might be right for
Bladder Cancer
Swiss Cancer Institute 40
Testing effectiveness (Phase 2)Looking for participantsNCT06833073
What this trial is testing

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Who this might be right for
Urinary Bladder NeoplasmsNon-Muscle Invasive Bladder NeoplasmsCarcinoma in Situ
Merck Sharp & Dohme LLC 308
Early research (Phase 1)Study completedNCT05085977
What this trial is testing

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

Who this might be right for
Non-muscle Invasive Bladder Cancer
Protara Therapeutics 12
Early research (Phase 1)Study completedNCT03258593
What this trial is testing

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Who this might be right for
Urinary Bladder Neoplasms
National Cancer Institute (NCI) 15
Not applicableLooking for participantsNCT05463796
What this trial is testing

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

Who this might be right for
Cancer RiskCancer Predisposition SyndromeHereditary Cancer Prediction+28 more
Dana-Farber Cancer Institute 5,000
Testing effectiveness (Phase 2)Study completedNCT00003129
What this trial is testing

Chemotherapy in Treating Patients With Early-Stage Bladder Cancer

Who this might be right for
Bladder Cancer
Eastern Cooperative Oncology Group 75
Testing effectiveness (Phase 2)Ended earlyNCT02901548
What this trial is testing

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Who this might be right for
Carcinoma in Situ of BladderBladder Cancer
H. Lee Moffitt Cancer Center and Research Institute 17
Early research (Phase 1)WithdrawnNCT04109092
What this trial is testing

Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

Who this might be right for
Urinary Bladder Neoplasms
Eisai Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT07283835
What this trial is testing

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Who this might be right for
Non Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer
Lepu Biopharma Co., Ltd. 16
Large-scale testing (Phase 3)Looking for participantsNCT05024773
What this trial is testing

Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

Who this might be right for
Bladder Carcinoma in Situ (CIS)
Fidia Farmaceutici s.p.a. 112
Large-scale testing (Phase 3)Active Not RecruitingNCT04452591
What this trial is testing

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Who this might be right for
Non Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer
CG Oncology, Inc. 190
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06310369
What this trial is testing

Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer

Who this might be right for
Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC 50
Large-scale testing (Phase 3)Ended earlyNCT01200992
What this trial is testing

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder NeoplasmNeoplasm Recurrence, LocalTransitional Cell, Carcinoma+2 more
Bioniche Life Sciences Inc. 84
Testing effectiveness (Phase 2)Looking for participantsNCT05951179
What this trial is testing

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Who this might be right for
Non-muscle Invasive Bladder Cancer
Protara Therapeutics 131
Testing effectiveness (Phase 2)Looking for participantsNCT04752722
What this trial is testing

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Who this might be right for
Superficial Bladder CancerNon-muscle Invasive Bladder Cancer With Carcinoma in Situ
enGene, Inc. 350
Testing effectiveness (Phase 2)Active Not RecruitingNCT04164082
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder Flat Urothelial Carcinoma In SituNon-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8+2 more
National Cancer Institute (NCI) 161
Large-scale testing (Phase 3)Study completedNCT00538850
What this trial is testing

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Who this might be right for
Cancer
INSYS Therapeutics Inc 130
Early research (Phase 1)Ended earlyNCT05014139
What this trial is testing

Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Who this might be right for
Urinary Bladder NeoplasmsCarcinoma in SituCarcinoma Transitional Cell+2 more
Astellas Pharma Global Development, Inc. 37
Load More Results